Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety
Metastatic Colorectal Cancer
DRUG: Glumetinib Combined with Fruquintinib
Recommended dose for Phase II, The dose determined during dose-escalation trials for use in Phase II studies, typically based on safety and tolerability data., Up to approximately 18 Weeks|Objective response rate(ORR), In the phase II study,CR + PR rate according to the RECIST version 1.1 guidelines., Up to approximately 18 Weeks
Maximum tolerated dose(MTD), The highest dose identified in dose-escalation trials that does not cause dose-limiting toxicities (DLTs)., Up to approximately 18 Weeks|Dose-limiting toxicity（DLT）, Severe or intolerable toxicity events related to the study drug within a specified time window, which may influence dose-escalation decisions., Up to approximately 18 Weeks|Assess Adverse Events, Assess adverse events according to the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0, up to 12 months|Disease control rate（DCR）, Proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD)., Up to approximately 18 Weeks|Overall Survival (OS), Overall survival is defined as the time from enrollment to death due to any cause., Up to approximately 36 Months|Objective Response Rate (ORR), In Phase I studies, CR + PR rate according to the RECIST version 1.1 guidelines., Up to approximately 18 Weeks|Progression-free survival（PFS）, Time from enrollment to disease progression (based on imaging or clinical assessment) or death from any cause., Up to approximately 18 Weeks
Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety